Cindy C. M. van Rijt-Van de Westerlo

Cindy C. M. van Rijt-Van de Westerlo

Auto-generated profile, based on publicly available information

Cindy C. M. van Rijt-Van de Westerlo

Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Molecular Endocrinology
Verified
Journal Article
Closed access
EJErik Jansen
Erik Jansen
JLJoop S. E. Laven
Joop S. E. Laven
HDHenri B. R. Dommerholt
Henri B. R. Dommerholt
JPJan Polman
Jan Polman
CRCindy van Rijt
Cindy van Rijt
BFBart C. J. M. Fauser
Bart C. J. M. Fauser
Polycystic ovary syndrome (PCOS) represents the most common cause of anovulatory infertility and affects 5-10% of women of reproductive age. The etiology of PCOS is still unknown. The current study is the first to describe consistent differences in gene expression profiles in human ovaries comparing PCOS patients vs. healthy normoovulatory individuals. The microarray analysis of PCOS vs. normal ovaries identifies dysregulated expression of genes encoding components of several biological pathways or systems such as Wnt signaling, extracellular matrix components, and immunological factors. Resulting data may provide novel clues for ovarian dysfunction in PCOS. Intriguingly, the gene expression profiles of ovaries from (long-term) androgen-treated female-to-male transsexuals (TSX) show considerable overlap with PCOS. This observation provides supportive evidence that androgens play a key role in the pathogenesis of PCOS. Presented data may contribute to a better understanding of dysregulated pathways in PCOS, which might ultimately reveal novel leads for therapeutic intervention.

Verified
Journal Article
Open access
PDF file
ARAlejandra Ruiz-Zapata
Alejandra Ruiz-Zapata
AHAndrea Heinz
Andrea Heinz
MKManon Heleen Kerkhof
Manon Heleen Kerkhof
CRCindy van de Westerlo-Van Rijt
Cindy van de Westerlo-Van Rijt
CSChristian E. H. Schmelzer
Christian E. H. Schmelzer
EOEgbert Oosterwijk
Egbert Oosterwijk
Fibroblast to myofibroblast differentiation is a key feature of wound-healing in soft tissues, including the vagina. Vaginal fibroblasts maintain the integrity of the vaginal wall tissues, essential to keep pelvic organs in place and avoid pelvic organ prolapse (POP). The micro-environment of vaginal tissues in POP patients is stiffer and has different extracellular matrix (ECM) composition than healthy vaginal tissues. In this study, we employed a series of matrices with known stiffnesses, as well as vaginal ECMs, in combination with vaginal fibroblasts from POP and healthy tissues to investigate how matrix stiffness and composition regulate myofibroblast differentiation in vaginal fibroblasts. Stiffness was positively correlated to production of α-smooth muscle actin (α-SMA). Vaginal ECMs induced myofibroblast differentiation as both α-SMA and collagen gene expressions were increased. This differentiation was more pronounced in cells seeded on POP-ECMs that were stiffer than those derived from healthy tissues and had higher collagen and elastin protein content. We showed that stiffness and ECM content regulate vaginal myofibroblast differentiation. We provide preliminary evidence that vaginal fibroblasts might recognize POP-ECMs as scar tissues that need to be remodeled. This is fundamentally important for tissue repair, and provides a rational basis for POP disease modelling and therapeutic innovations in vaginal reconstruction.

30 May 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
AHAntoine G. van der Heijden
Antoine G. van der Heijden
LMLourdes Mengual
Lourdes Mengual
MIMercedes Ingelmo-Torres
Mercedes Ingelmo-Torres
JLJuan Jose Lozano
Juan Jose Lozano
CWCindy C. M. van Rijt-Van de Westerlo
Cindy C. M. van Rijt-Van de Westerlo
AAAntonio Alcaraz
Antonio Alcaraz
Current standard methods used to detect and monitor bladder cancer (BC) are invasive or have low sensitivity. This study aimed to develop a urine methylation biomarker classifier for BC monitoring and validate this classifier in patients in follow-up for bladder cancer (PFBC). Voided urine samples (N = 725) from BC patients, controls, and PFBC were prospectively collected in four centers. Finally, 626 urine samples were available for analysis. DNA was extracted from the urinary cells and bisulfite modificated, and methylation status was analyzed using pyrosequencing. Cytology was available from a subset of patients (N = 399). In the discovery phase, seven selected genes from the literature (CDH13, CFTR, NID2, SALL3, TMEFF2, TWIST1, and VIM2) were studied in 111 BC and 57 control samples. This training set was used to develop a gene classifier by logistic regression and was validated in 458 PFBC samples (173 with recurrence). A three-gene methylation classifier containing CFTR, SALL3, and TWIST1 was developed in the training set (AUC 0.874). The classifier achieved an AUC of 0.741 in the validation series. Cytology results were available for 308 samples from the validation set. Cytology achieved AUC 0.696 whereas the classifier in this subset of patients reached an AUC 0.768. Combining the methylation classifier with cytology results achieved an AUC 0.86 in the validation set, with a sensitivity of 96%, a specificity of 40%, and a positive and negative predictive value of 56 and 92%, respectively. The combination of the three-gene methylation classifier and cytology results has high sensitivity and high negative predictive value in a real clinical scenario (PFBC). The proposed classifier is a useful test for predicting BC recurrence and decrease the number of cystoscopies in the follow-up of BC patients. If only patients with a positive combined classifier result would be cystoscopied, 36% of all cystoscopies can be prevented.

27 August 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
ARAgus Ardy Hariandy Rizal
Agus Ardy Hariandy Rizal
AHA. Marije Hoogland
A. Marije Hoogland
FSFrank Smit
Frank Smit
SJSander Jannink
Sander Jannink
CWCindy van Rijt-Van de Westerlo
Cindy van Rijt-Van de Westerlo
Jack SchalkenJack Schalken
Jack Schalken

1 March 2015 in Journal of Urology
Verified
Journal Article
Closed access
ARAgus Ardy Hariandy Rizal
Agus Ardy Hariandy Rizal
GVGerald W. Verhaegh
Gerald W. Verhaegh
FSFrank P. Smit
Frank P. Smit
CWCindy van Rijt-Van de Westerlo
Cindy van Rijt-Van de Westerlo
IAInna Armandari
Inna Armandari
Jack SchalkenJack Schalken
Jack Schalken
Dihydrotestosterone is the main active androgen in the prostate and it has a role in prostate cancer progression. After androgen deprivation therapy androgen receptor signaling is still active in tumor cells. Persistent intratumor steroidogenesis and androgen receptor changes are responsible for this continued activity, which influences the efficacy of prostate cancer treatment. We hypothesized that combining a 5α-reductase inhibitor and an antiandrogen would block intratumor androgen synthesis and androgen receptor protein activity. Thus, it would act synergistically to reduce tumor cell proliferation. The expression level of 5α-reductase and androgen receptor in endocrine therapy naïve prostate cancer and castration resistant prostate cancer tissues, and cell line models was determined by microarray and quantitative polymerase chain reaction analysis. Intracellular androgen was measured with radioimmunoassay. Tumor cell proliferation was determined using coloric MTT assay. The synergistic effects of combination treatments on tumor cell proliferation were calculated using the Chou-Talalay equation. In all prostate cancer cases 5α-reductase-1 and 3 were up-regulated. Androgen receptor was up-regulated in metastatic prostate cancer and castration resistant prostate cancer cases. The 5α-reductase inhibitor dutasteride effectively decreased dihydrotestosterone production in prostate cancer and castration resistant prostate cancer cell lines. Furthermore, dutasteride combined with the novel antiandrogen enzalutamide synergistically suppressed endocrine therapy naïve prostate cancer and castration resistant prostate cancer cell proliferation. In this study the combination of a 5α-reductase inhibitor and (novel) antiandrogens synergistically inhibited tumor cell proliferation. These findings support clinical studies of combinations of a 5α-reductase inhibitor and (novel) antiandrogens as first line treatment of prostate cancer and castration resistant prostate cancer.

Verified
Journal Article
Open access
PDF file
AMArjanneke van de Merbel
Arjanneke van de Merbel
Onno van HooijOnno van Hooij
Onno van Hooij
GHGeertje van der Horst
Geertje van der Horst
CWCindy C. M. van Rijt-Van de Westerlo
Cindy C. M. van Rijt-Van de Westerlo
MMMaaike H. van der Mark
Maaike H. van der Mark
GPGabri van der Pluijm
Gabri van der Pluijm
Transformed epithelial cells can activate programs of epithelial plasticity and switch from a sessile, epithelial phenotype to a motile, mesenchymal phenotype. This process is linked to the acquisition of an invasive phenotype and the formation of distant metastases. The development of compounds that block the acquisition of an invasive phenotype or revert the invasive mesenchymal phenotype into a more differentiated epithelial phenotype represent a promising anticancer strategy. In a high-throughput assay based on E-cadherin (re)induction and the inhibition of tumor cell invasion, 44,475 low molecular weight (LMW) compounds were screened. The screening resulted in the identification of candidate compounds from the PROAM02 class. Selected LMW compounds activated E-cadherin promoter activity and inhibited cancer cell invasion in multiple metastatic human cancer cell lines. The intraperitoneal administration of selected LMW compounds reduced the tumor burden in human prostate and breast cancer in vivo mouse models. Moreover, selected LMW compounds decreased the intra-bone growth of xenografted human prostate cancer cells. This study describes the identification of the PROAM02 class of small molecules that can be exploited to reduce cancer cell invasion and metastases. Further clinical evaluation of selected candidate inhibitors is warranted to address their safety, bioavailability and antitumor efficacy in the management of patients with aggressive cancers.